Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.83 USD
−135.35 M USD
0.00 USD
46.20 M
About Monte Rosa Therapeutics, Inc.
Sector
Industry
CEO
Markus Warmuth
Website
Headquarters
Boston
Founded
2019
FIGI
BBG00X2VGZQ3
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GLUE is 6.93 USD — it has increased by 6.45% in the past 24 hours. Watch Monte Rosa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monte Rosa Therapeutics, Inc. stocks are traded under the ticker GLUE.
GLUE stock has fallen by −11.94% compared to the previous week, the month change is a −15.90% fall, over the last year Monte Rosa Therapeutics, Inc. has showed a 24.64% increase.
We've gathered analysts' opinions on Monte Rosa Therapeutics, Inc. future price: according to them, GLUE price has a max estimate of 20.00 USD and a min estimate of 11.00 USD. Watch GLUE chart and read a more detailed Monte Rosa Therapeutics, Inc. stock forecast: see what analysts think of Monte Rosa Therapeutics, Inc. and suggest that you do with its stocks.
GLUE reached its all-time high on Sep 7, 2021 with the price of 45.56 USD, and its all-time low was 2.44 USD and was reached on Oct 25, 2023. View more price dynamics on GLUE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GLUE stock is 11.39% volatile and has beta coefficient of 1.50. Track Monte Rosa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Monte Rosa Therapeutics, Inc. there?
Today Monte Rosa Therapeutics, Inc. has the market capitalization of 425.76 M, it has decreased by −9.87% over the last week.
Yes, you can track Monte Rosa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Monte Rosa Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
GLUE earnings for the last quarter are −0.29 USD per share, whereas the estimation was −0.47 USD resulting in a 38.89% surprise. The estimated earnings for the next quarter are 0.18 USD per share. See more details about Monte Rosa Therapeutics, Inc. earnings.
Monte Rosa Therapeutics, Inc. revenue for the last quarter amounts to 9.20 M USD, despite the estimated figure of 2.64 M USD. In the next quarter, revenue is expected to reach 51.19 M USD.
GLUE net income for the last quarter is −23.86 M USD, while the quarter before that showed −30.31 M USD of net income which accounts for 21.28% change. Track more Monte Rosa Therapeutics, Inc. financial stats to get the full picture.
No, GLUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 133.00 employees. See our rating of the largest employees — is Monte Rosa Therapeutics, Inc. on this list?
Like other stocks, GLUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monte Rosa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monte Rosa Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monte Rosa Therapeutics, Inc. stock shows the neutral signal. See more of Monte Rosa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.